ID   SUP-B15
AC   CVCL_0103
SY   Sup-B15; SUPB-15; SUPB15; SupB15; SupB15W; SupB15WT
DR   CLO; CLO_0009161
DR   EFO; EFO_0006763
DR   AddexBio; C0003019/4892
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1929
DR   BCRJ; 0229
DR   BioSample; SAMN03473114
DR   BioSample; SAMN10987666
DR   CCLE; SUPB15_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CCRID; 3131C0001000700190
DR   Cell_Model_Passport; SIDM01176
DR   Cosmic; 1012120
DR   Cosmic; 1130245
DR   Cosmic; 1498420
DR   Cosmic; 1524821
DR   Cosmic; 1630017
DR   Cosmic; 2491077
DR   Cosmic-CLP; 1247871
DR   DepMap; ACH-000059
DR   DSMZ; ACC-389
DR   GDSC; 1247871
DR   GEO; GSM236806
DR   GEO; GSM236842
DR   GEO; GSM887658
DR   GEO; GSM888750
DR   GEO; GSM1374913
DR   GEO; GSM1670490
DR   IARC_TP53; 30174
DR   IZSLER; BS TCL 238
DR   LiGeA; CCLE_418
DR   LINCS_LDP; LCL-1041
DR   PharmacoDB; SUPB15_1518_2019
DR   PRIDE; PXD000394
DR   Progenetix; CVCL_0103
DR   Wikidata; Q54970859
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3162827;
RX   PubMed=7630190;
RX   PubMed=7888679;
RX   PubMed=8704231;
RX   PubMed=9067587;
RX   PubMed=9108419;
RX   PubMed=9823951;
RX   PubMed=10071072;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25576301;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: ~18 hours (PubMed=3162827); ~60 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=3162827; PubMed=10071072; PubMed=15843827; PubMed=25485619; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.5%; East Asian, North=0.25%; East Asian, South=0.2%; South Asian=1.01%; European, North=70.33%; European, South=27.71% (PubMed=30894373).
CC   Discontinued: AddexBio; C0003019; probable.
CC   Discontinued: BCRJ; 0229; probable.
CC   Derived from sampling site: Bone marrow.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8,14
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 28,31
ST   D3S1358: 15,16
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 11,14
ST   FGA: 19,20
ST   Penta D: 9,12
ST   Penta E: 21
ST   TH01: 6,9.3
ST   TPOX: 8,9
ST   vWA: 15,17
DI   NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_A308 ! SUP-B13
SX   Male
AG   9Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 32
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3162827;
RA   Naumovski L., Morgan R., Hecht F., Link M.P., Glader B.E., Smith S.D.;
RT   "Philadelphia chromosome-positive acute lymphoblastic leukemia cell
RT   lines without classical breakpoint cluster region rearrangement.";
RL   Cancer Res. 48:2876-2879(1988).
//
RX   PubMed=7630190;
RA   Zhou M., Gu L., James C.D., He J., Yeager A.M., Smith S.D.,
RA   Findley H.W.;
RT   "Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines
RT   established from children with acute lymphoblastic leukemia.";
RL   Leukemia 9:1159-1161(1995).
//
RX   PubMed=7888679; DOI=10.1182/blood.V85.6.1608.bloodjournal8561608;
RA   Zhou M., Yeager A.M., Smith S.D., Findley H.W.;
RT   "Overexpression of the MDM2 gene by childhood acute lymphoblastic
RT   leukemia cells expressing the wild-type p53 gene.";
RL   Blood 85:1608-1614(1995).
//
RX   PubMed=8704231; DOI=10.1182/blood.V88.3.785.785;
RA   Kim D.-H., Moldwin R.L., Vignon C., Bohlander S.K., Suto Y.,
RA   Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D.;
RT   "TEL-AML1 translocations with TEL and CDKN2 inactivation in acute
RT   lymphoblastic leukemia cell lines.";
RL   Blood 88:785-794(1996).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=9108419; DOI=10.1182/blood.V89.8.2986;
RA   Findley H.W., Gu L., Yeager A.M., Zhou M.;
RT   "Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with
RT   p53 status and sensitivity to apoptosis in childhood acute
RT   lymphoblastic leukemia.";
RL   Blood 89:2986-2993(1997).
//
RX   PubMed=9823951; DOI=10.1038/sj.leu.2401198;
RA   Zhou M., Gu L., Yeager A.M., Findley H.W.;
RT   "Sensitivity to Fas-mediated apoptosis in pediatric acute
RT   lymphoblastic leukemia is associated with a mutant p53 phenotype and
RT   absence of Bcl-2 expression.";
RL   Leukemia 12:1756-1763(1998).
//
RX   PubMed=10071072; DOI=10.1016/s0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25576301; DOI=10.1074/mcp.M114.042812;
RA   Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.;
RT   "Mass spectrometry of human leukocyte antigen class I peptidomes
RT   reveals strong effects of protein abundance and turnover on antigen
RT   presentation.";
RL   Mol. Cell. Proteomics 14:658-673(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//